Castle Biosciences Statistics
Share Statistics
Castle Biosciences has 28.01M shares outstanding. The number of shares has increased by 3.07% in one year.
| Shares Outstanding | 28.01M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | 0.47% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 27.16M |
| Failed to Deliver (FTD) Shares | 10 |
| FTD / Avg. Volume | 0% |
Short Selling Information
The latest short interest is 1.61M, so 5.74% of the outstanding shares have been sold short.
| Short Interest | 1.61M |
| Short % of Shares Out | 5.74% |
| Short % of Float | 5.92% |
| Short Ratio (days to cover) | 4.27 |
Valuation Ratios
The PE ratio is -10.06 and the forward PE ratio is -16.15.
| PE Ratio | -10.06 |
| Forward PE | -16.15 |
| PS Ratio | 2.63 |
| Forward PS | 3.1 |
| PB Ratio | 1.48 |
| P/FCF Ratio | -30.05 |
| PEG Ratio | n/a |
Enterprise Valuation
Castle Biosciences Inc. has an Enterprise Value (EV) of 494.86M.
| EV / Earnings | -8.61 |
| EV / Sales | 2.25 |
| EV / EBITDA | -10.99 |
| EV / EBIT | -7.28 |
| EV / FCF | -25.71 |
Financial Position
The company has a current ratio of 6.2, with a Debt / Equity ratio of 0.
| Current Ratio | 6.2 |
| Quick Ratio | 6.04 |
| Debt / Equity | 0 |
| Total Debt / Capitalization | 0.29 |
| Cash Flow / Debt | -4.95 |
| Interest Coverage | -6179.73 |
Financial Efficiency
Return on equity (ROE) is -0.15% and return on capital (ROIC) is -16.75%.
| Return on Equity (ROE) | -0.15% |
| Return on Assets (ROA) | -0.13% |
| Return on Capital (ROIC) | -16.75% |
| Revenue Per Employee | 309.56K |
| Profits Per Employee | -80.94K |
| Employee Count | 710 |
| Asset Turnover | 0.48 |
| Inventory Turnover | 5.66 |
Taxes
| Income Tax | 101.00K |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by 43.65% in the last 52 weeks. The beta is 0.98, so Castle Biosciences 's price volatility has been higher than the market average.
| Beta | 0.98 |
| 52-Week Price Change | 43.65% |
| 50-Day Moving Average | 31.26 |
| 200-Day Moving Average | 25.41 |
| Relative Strength Index (RSI) | 41.6 |
| Average Volume (20 Days) | 397.92K |
Income Statement
In the last 12 months, Castle Biosciences had revenue of $219.79M and earned -$57.47M in profits. Earnings per share was $-2.14.
| Revenue | 219.79M |
| Gross Profit | 174.81M |
| Operating Income | -67.98M |
| Net Income | -57.47M |
| EBITDA | -45.02M |
| EBIT | -67.98M |
| Earnings Per Share (EPS) | -2.14 |
Balance Sheet
The company has $98.84M in cash and $15.34M in debt, giving a net cash position of $83.51M.
| Cash & Cash Equivalents | 98.84M |
| Total Debt | 15.34M |
| Net Cash | 83.51M |
| Retained Earnings | -218.37M |
| Total Assets | 514.57M |
| Working Capital | 300.48M |
Cash Flow
In the last 12 months, operating cash flow was -$5.63M and capital expenditures -$13.62M, giving a free cash flow of -$19.25M.
| Operating Cash Flow | -5.63M |
| Capital Expenditures | -13.62M |
| Free Cash Flow | -19.25M |
| FCF Per Share | -0.72 |
Margins
Gross margin is 79.53%, with operating and profit margins of -30.93% and -26.15%.
| Gross Margin | 79.53% |
| Operating Margin | -30.93% |
| Pretax Margin | -26.1% |
| Profit Margin | -26.15% |
| EBITDA Margin | -20.49% |
| EBIT Margin | -30.93% |
| FCF Margin | -8.76% |
Dividends & Yields
CSTL does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -7.42% |
| FCF Yield | -2.38% |
Analyst Forecast
The average price target for CSTL is $40, which is 38.7% higher than the current price. The consensus rating is "Buy".
| Price Target | $40 |
| Price Target Difference | 38.7% |
| Analyst Consensus | Buy |
| Analyst Count | 8 |
Scores
| Altman Z-Score | 7.47 |
| Piotroski F-Score | 7 |